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Abstract. The genetics background underlying the aggres-
siveness of chondrosarcoma (CS) is poorly understood. One 
possible cause of malignant transformation is chromosomal 
instability, which involves an error in mitotic segregation due 
to numerical and/or functional abnormalities of centrosomes. 
The present study aimed to evaluate centrosome amplifica-
tion in cryopreserved samples of tumor tissue from patients 
with CS. An analysis was performed on 3 primary cultures 
of tumors from patients who underwent surgery between 
January 2012 and December 2012 at the Department of 
Orthopedics at the Barretos Cancer Hospital (Barretos, 
Brazil). Additionally, cryopreserved tumor specimens were 
analyzed from 10 patients. The data were assessed using 
immunocytochemistry and immunohistochemistry staining 
techniques with monoclonal antibody anti-γ-tubulin. A total of 
4 samples of CS cultured cells were obtained from 3 patients. 
A recurrence of a histological grade III tumor was detected 
in a female patient with Ollier's syndrome. The other 2 cases 
were grade I and III. The incidence of centrosome amplifica-
tion in the primary cultures ranged from 15-64% of the cells. 
Whereas control cultured fibroblasts showed baseline levels 
of 4% amplified cells. For the cryopreserved specimens, two 
independent observers analyzed each sample and counted 
the cells stained with γ-tubulin, verifying the percentage of 
affected cells to be a mean of 14%, with the number of clusters 
ranging between 0-6 per slide. In conclusion, centrosome 
amplification was found to be a consistent biological feature 
of CS and may underlie chromosomal instability in this tumor.
Introduction
Chondrosarcoma (CS) is a neoplasm of mesenchymal origin 
that forms cartilage-pattern tumors of the bone and consists of 
different histological subtypes (1).
This tumor is considered to be resistant to chemotherapy 
and radiotherapy, and the mainstay treatment is surgical (2,3). 
Several attempts have been made to identify reliable molecular 
markers and therapeutic targets for CS. However, none of these 
biological markers have been proven to provide independent 
prognostic information (4-6).
The majority of genetic analyses performed on CS were 
performed on a heterogeneous group that included all different 
subtypes of CS; ploidy-analysis of CS has been described and 
aneuploidy is more frequently found in high-grade CS (7,8).
There have been, to date, few studies on CS cell lines. This 
may be associated with the low proliferation rates of the tumor 
cells and the difficulty in reproducing an adequate environ-
ment for CS development (9).
The centrosome is a non-membranous organelle usually 
found in the periphery of the nucleus; it consists of a pair of 
orthogonally arranged, barrel-shaped centrioles and numerous 
different proteins that surround the pericentriolar material. 
During interphase, the centrosome is responsible for organizing 
the microtubule network by directing the formation of the 
mitotic spindle (10). It has been demonstrated that the centro-
some amplification is linked to chromosomal instability and the 
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prognosis of patients with malignant tumors (11). Centrosome 
amplification has been detected in several types of malignan-
cies and borderline sarcomas, including osteosarcoma (7,12,13). 
Moskovsky et al reported that centrosome amplification is 
present in benign giant cell tumors of the bone, demonstrating 
that this phenomenon is not characteristic of malignant giant 
cell tumors. In addition, the study showed that centrosome 
amplification was prognostic for clinical behavior (14).
The present study aimed to characterize centrosome 
amplification in CS using cryopreserved tissue samples and 
tissue cultures.
Materials and methods
Tumor samples. The study was conducted with cryopreserved 
CS tumor tissue samples from 10 patients treated surgically in 
the Barretos Cancer Hospital (Barretos, Brazil). Additionally, 
samples were used from the cultures of tumors from 3 patients 
who underwent surgery in the Department of Orthopedics at the 
Barretos Cancer Hospital. The study was approved by the Insti-
tutional Ethical Committee of the Barretos Cancer Hospital.
Establishment of primary cultures. In this study, centrosome 
amplification was evaluated in CS using cryopreserved tissues 
and primary cell cultures. A commercial culture of normal 
fibroblasts, lineage CCD-1059 SK, was used as a control 
(Thermo Fisher Scientific Inc., Waltham, MA, USA). The 
cells from the tumor samples were cultured for 7-25 days in 
an incubator with a humidified atmosphere containing 5% 
CO2 at 37˚C, standing for ~7 days until confluence, prior to 
cytogenetic and morphological evaluation (Fig. 1).
Tumors were reviewed by a pathologist and graded and 
staged according to World Health Organization classification (1). 
Primary tumor specimens were finely minced, treated with 
trypsin and cultured in Dulbecco's modified Eagle's medium 
(Thermo Fisher Scientific Inc.) supplemented with 10% fetal 
bovine serum (Thermo Fisher Scientific Inc.) and 1% antibiotics.
Analysis of centrosome amplification
Immunohistochemistry/immunocytochemistry. The cells 
were cultured on coverslips for 3-4 days, washed with phos-
phate‑buffered saline, fixed with 4% paraformaldehyde and 
then permeabilized with Triton-X100. An UltraVision Plus 
detection system (Thermo Fisher Scientific Inc.) was used for 
centrosome immunostaining and analysis.
The cells were incubated overnight with mouse monoclonal 
anti-γ-tubulin (1:2,000 dilution; Sigma-Aldrich, St. Louis, 
MO, USA) and blocked with Ultra‑V‑Block (Thermo Fisher 
Scientific Inc.). All incubations were performed at 31˚C with 
primary antibodies for 30 min, and thereafter with the bioti-
nylated secondary antibody (Thermo Fisher Scientific Inc.) for 
60 min. After 3,3'‑diaminobenzidine exposure, the slides were 
subsequently stained with hematoxylin.
To determine centrosome numbers, the cells were subjected 
to immunostaining using a mouse monoclonal anti-γ-tubulin 
antibody (Sigma-Aldrich), as described previously (15).
Statistical analysis. The Lin coefficient of concordance 
(MedCalc Version 11.1.1.0; MedCalc Software bvba, Ostend, 
Belgium) was used, considering a 95% confidence interval, 
as it is a test that combines a measure of accuracy (Pearson 
correlation coefficient; MedCalc Version 11.1.1.0) with another 
measure of accuracy (Cb) to determine how the observed data 
deviate from the line of identity (i.e., 45˚ line), with variance 
based on to the distance of the data to the line (the accuracy 
of the data), and on the dispersion of the data around the line 
(data accuracy). Given the number of categories observed in the 
total score, the Lin concordance coefficient was also adopted 
to assess the degree of agreement between the two observers. 
For this coefficient, excellent agreement was defined as a 
value >0.900, a suitable value ranged from 0.600-0.900 and 
an unsatisfactory value was <0.600.
Results
Primary cultures. Cultures from the tumor samples of 3 patients 
who underwent surgery in 2012 in Barretos Cancer Hospital were 
analyzed. The clinical data are summarized in Table I. Centro-
some amplification was detected in the normal fibroblasts, with 
5% of cells exhibiting increased numbers of centrosomes.
Following primary culture, to establish the patterning 
process, 2 of the samples were subjected to immunocy-
tochemistry (Fig. 2A) and 1 samples was subjected to 
immunofluorescence (Fig. 2B) analysis, as indicated in Table II.
Centrosome amplification, assessed using the immuno-
cytochemistry technique (Fig. 2A), was observed in 64% 
of grade III CS Ollier's syndrome cells and in 76% of cells 
from the recurrence in the same patient (case 1). Amplifica-
tion occurred in 48% of the grade I cells (case 2). Using the 
fluorescence technique, amplification was observed in 15% of 
the grade III CS cells (case 3). 
Cluster formation was also observed in the cultures. In 
case 1, one cluster occurred in 15% of the cells and two clusters 
occurred in 2%. In the recurrence, 16% of cells exhibited one 
cluster, 5% exhibited two clusters and 1% exhibited three clus-
ters. In grade I CS, one cluster was observed in 5% of nuclei 
and two clusters were observed in 1% of nuclei. As observed 
using the immunofluorescence technique, 8% of cells in the 
grade III CS (case 4) exhibited one cluster.
Figure 1. Establishment of primary chondrosarcoma cultures. Images 
obtained using an inverted microscope at x10 magnification. Trypan blue 
staining.
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A commercial culture of normal fibroblasts (CCD‑1059 SK 
lineage) was also established that served as a negative control; 
the amplification of centrosomes was observed in 5% of the 
control cells, as observed using immunocytochemistry.
Cryopreserved tissue. A total of 10 samples of cryopreserved 
CS tumor tissue samples stored in the tumor bank were 
Table II. Frequency of centrosome amplification in primary cultures of CS.
 Presence of centrosomes per cell (%) Clusters (%)
 ----------------------------------------------------------------------- -------------------------------------------------------------------------------------
Subtype Normal Amplified 1 Cluster  2 Clusters 3 Clusters
CS-Ollier's syndrome grade III 36 64 15 2 0
CS-Ollier's syndrome grade III  24 76 16 5 1
(sample of recurrence)     
CS grade I 52 48   5 1 0
CS grade III 85 15   8 0 0
CS, chondrosarcoma.
Table I. Clinical data of patients with sarcoma who underwent surgery in the Department of Orthopedics at the Barretos Cancer 
hospital.
Case Gender/age, yearsa Location Ch/Rdb Pathology Recurrence
1 F/35 Left humerus Yes/no CS-Ollier's syndrome grade III  Yes
2 F/50 Left distal femur No/no CS grade I No
3 M/42 Left shoulder and No/no CS grade III No
  suprascapular region
aAge at time of surgery; bprevious Ch or Rd. CS, chondrosarcoma; M, male; F, female; Ch, chemotherapy, Rd, radiotherapy. 
Figure 2. Primary chondrosarcoma culture (control) images (x1,000 mag-
nification), as determined by (A) immunocytochemistry (arrow indicates a 
cluster of centrosomes) and (B) immunofluorescence analysis.
  A
  B
Figure 3. Cryopreserved materials immunohistochemically‑stained for 
γ‑tubulin (optical microscopy, x200 magnification). (A) Case 9: Secondary, 
grade I. (B) Case 5: Primary myxoid, grade I.
  A
  B
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selected. The clinical data of the 10 patients who provided 
these samples are summarized in Table III.
Centrosome amplification. The centrosomes were analyzed 
using an optical microscope (x1,000 magnification). Two inde-
pendent observers analyzed each sample and counted the cells 
stained with γ-tubulin, verifying the percentage of affected cells 
(Fig. 3).
The results are shown in Table IV. Analyst A found the 
percentage of cells with amplifications ranged between 4 and 
19% (mean, 14%), while analyst B found that the percentage 
of cells with amplification ranged between 7 and 22% 
(mean, 14%).
With regard to the formation of clusters, analyst A found 
0-3 clusters per slide (mean, 0.8 clusters) and analyst B found 
between 0 and 6 clusters (mean, 1 cluster).
Data analysis. For the 10 cases evaluated, the data were 
analyzed using the Lin concordance coefficient. With regard 
to the percentage of cells with amplification, the estimates 
ranged from 0.2205‑0.9211 with 95% confidence. The concor-
dance correlation coefficient was 0.7213.
Table III. Main clinical data of the cryopreserved tissue using immunohistochemistry.
  Follow‑up     Functional  
 Gender  time,     status of 
Case /age, years months Location Pathology Metastasis Surgical type the member Last information
  1 M/65 29.31 Pelvis Classical grade I,  Yes, after Simple With Succumbed to
    primary diagnosis resection limitation cancer
  2 F/56 65.08 Chest Classical grade I,  No Simple Not Alive without
    primary  resection applicable disease
  3 F/21 9.66 Pelvis Classical grade II,  Yes,  Not Unknown Alive without
    primary at diagnosis operated  disease
  4 F/41 39.39 Lower Myxoid grade I,  Yes,  Amputated Amputated Alive without
   limb primary at diagnosis   disease
  5 F/52 65.41 Pelvis Myxoid grade I,  No Simple Functional Alive without
    primary  resection  disease
  6 F/46 38.44 Shoulder Classical grade II,  No Simple Functional Alive without
   girdle secondary  resection  disease
  7 M/27 42.25 Upper Classical grade I,  No Amputated Amputated Alive without
   limb secondary    disease
  8 F/37 30.46 Lower Classical grade II,  No Resection and With Alive without
   limb secondary  prosthesis limitation disease
  9 F/25 1.05 Shoulder Classical grade I,  No Simple Functional Alive without
   girdle secondary  resection  disease
10 M/42 17.74 Shoulder Classical grade III,  Yes,  Amputated Amputated Alive without
   girdle primary at diagnosis   disease
Table IV. Frequency of centrosome amplification and the frequency of clusters in 10 cryopreserved chondrosarcoma tissues 
(analysis conducted by two independent observers).
 Percentage frequency of centrosome amplification Number of clusters of centrosomes
 ---------------------------------------------------------------------------------------------- -----------------------------------------------------------------------
Case  Analyst A (%) Analyst B (%) Analyst A Analyst B
  1 18.0 22.0 0 0
  2 21.0 20.0 3 6
  3 13.9   6.9 1 1
  4   9.3   9.3 0 0
  5 19.0 20.0 1 1
  6 17.0 13.0 2 1
  7 10.0 10.0 0 0
  8 16.0 13.0 0 0
  9 14.0 11.0 0 0
10   4.0 10.0 1 1
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With regard to the number of clusters, the data were analyzed 
using the Lin concordance coefficient, and with 95% confi-
dence, it is estimated that the range was from 0.4948-0.8861. 
The concordance correlation coefficient was 0.7500.
Discussion
The data in the present study revealed that the CS genetic profile 
adopts several alterations associated with centrosome amplifica-
tion, as previously supposed (10-12). The present study describes 
arguments in favor of the premise that centrosome amplification 
is a critical biological event for the development of this malig-
nancy. The study of centrosome alterations is multifaceted and 
time consuming, and accordingly requires appropriate expertise 
of the professionals involved and tests to evaluate the results. 
The technical procedures to maintain primary cultures of cancer 
offer varying degrees of difficulty and so the results are not 
always satisfactory. Sarcoma cultures are even more complex 
and difficult to effectively conduct. Therefore, the establishment 
of primary cultures of CS produces a working model that is 
quite promising. In the present study, the primary cultures of 
CS were prepared using samples from three cases with different 
histopathological classifications: 1 grade I case, 1 grade III case 
and 1 grade III case with CS recurrence.
In general, the findings demonstrated that in the cases 
of primary cultures stained with the immunocytochemistry 
technique using fluorescent development, the assessment of 
centrosomes was clear, without any ill-defined images. The 
amplified centrosomes were positively demonstrated in all cases 
when compared with normal fibroblasts, with demonstrated 
percentages of amplified centrosomes ranging from 15‑64%. 
Notably, even the grade I CS showed amplified centrosomes, 
implying that the amplification of centrosomes can be hypoth-
esized as a precursor to malignant transformation. A sample of 
recurrent tumor revealed amplified centrosomes, as was previ-
ously observed in the primary CS sample of the same patient, but 
with an increased number of malignant cells with more than two 
centrosomes. Another case exhibited a low rate of centrosome 
amplification, showing only 15% of cells with amplification. This 
finding is not unexpected, as centrosome amplification in bone 
and soft tissue tumors has been observed in tumors classified as 
benign or with local aggressiveness (as in giant cell tumors) or 
even in malignant bone tumors such as osteosarcoma (14).
Analysis of the cryopreserved tissues showed amplification 
percentages ranging from 4-19% (mean, 14%), which is lower 
compared with the primary culture. This difference may be 
due to the quality of the sample, and the fact that the primary 
culture tended to be the most similar to the tumor in vivo. The 
presence of centrosome amplification can also be represented 
by the formation of clustering, but the mechanism is not fully 
understood. Abnormalities in centrosome organization are 
under investigation in oncology settings and the findings have 
been observed in in vivo samples and cultured cells (12). In 
the present study, 2 cases showed single clusters occurring 
in 15 and 16% of the cells, respectively, compared with the 
normal fibroblasts, which showed a maximum of 3%. However, 
a reduced number of clusters was also observed in CS, with 
1 case exhibiting 5% of malignant cells with one cluster and 
1% of malignant cells with two clusters. The remaining case 
showed only 8% of malignant cells with one cluster each. 
This significant variation in centrosome clusters suggests 
that cluster formation is not a pivotal phenomenon for CS 
behavior. Setoguchi et al observed similar findings in sarcomas 
of dogs (16). Different types of sarcomas have shown hyper-
amplification of centrosomes associated with chromosome 
instability, which was credited as a novel tumor marker (12).
In this study, cryopreserved tissues in the percentages of 
clusters were smaller than those found in culture, ranging from 
1 to 6% of cells with clusters. This difference may be occurring 
due to the characteristic of the sample; the cell culture would 
be the closest representation of the tumor in vivo. Another fact 
that was found is that the clusters found in the cryopreserved 
tissues were smaller than those in the cell cultures.
Centrosome amplification may predict the aggressive 
behavior of tumors, and other findings in the literature have 
associated this process with an alteration of centrosomes, with 
chromosomal instabilities found in other bone tumors such as 
osteosarcoma, as anticipated (12). The present results support 
these premises and concur that centrosome amplification is 
widely found in CS and likely represents a major mechanism 
underlying the generation of multipolar mitoses, chromosome 
instabilities and aneuploidy.
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